Cohance Lifesciences (formerly Suven Pharmaceuticals Limited) has announced a conference call for investors and analysts on Tuesday, May 12, 2026, at 6:30 pm IST. The call is being organised to discuss the company's audited financial results for Q4 and FY26, which are scheduled to be declared earlier in the day. The event will feature senior management participation and is designed to provide stakeholders with direct access to the company's financial performance update.

Conference Call Format and Agenda

The conference call will be initiated with a brief management discussion covering the Q4 and FY26 results, followed by an interactive Question & Answer session. This format allows investors and analysts to seek clarifications and engage directly with the company's senior management on the reported financial outcomes.

Dial-In Details and Access Information

Participants can connect to the conference call using the following dial-in details. Callers are advised to dial in 5–10 minutes prior to the scheduled start time to ensure timely connectivity.

Participants also have the option to pre-register via the provided link to receive dial-in numbers, a passcode, and a PIN directly on their registered email address, enabling them to join the call without waiting for an operator.

Investor Relations Contact

For further information regarding the conference call, stakeholders may reach out to the following contacts:

• Cyndrella Carvalho, Head – Investor Relations, Cohance Lifesciences Limited

  • Tel: 040 2354 3311
  • Email: cyndrella.carvalho@cohance.com

• Gavin Desa, CDR India

  • Tel: +91 98206 37649
  • Email: gavin@cdr-india.com

Cohance Lifesciences is headquartered at 202, A-Wing, Galaxy Towers, Plot No. 1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad – 500081, Telangana, with its registered office at 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra – 400093.

Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) has notified the stock exchanges of an upcoming board meeting, in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was filed on May 6, 2026, and signed by Company Secretary & Compliance Officer Sisir K. Mishra.

Board Meeting Details

The following key details have been disclosed regarding the scheduled board meeting:

Agenda and Compliance

The board meeting has been convened, inter alia, to consider and approve the Audited Financial Results of the company — both Standalone and Consolidated — for the quarter and financial year ended March 31, 2026. The intimation was made in accordance with applicable SEBI listing regulations, underscoring the company's commitment to regulatory compliance and timely disclosure.

Trading Window Closure

In continuation of the company's earlier communication dated March 27, 2026 regarding the closure of the Trading Window, designated persons and their immediate relatives are restricted from dealing in the shares of the company. The Trading Window shall remain closed until May 14, 2026, two days after the scheduled board meeting date.

Company Background

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited, is headquartered at Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, Telangana, with its registered office located in Andheri East, Mumbai, Maharashtra.